Driving Innovation,
Delivering Value

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel oncology therapies that address emerging targets in oncology. Internally discovered pipeline candidates at Ryvu use diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules and antibody-drug conjugates directed at kinases, synthetic lethality, and immuno-oncology targets.

Publications

    • pdf file

      Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors

      Download
    • pdf file

      Discovery of novel MTA-cooperative PRMT5 preclinical candidate as targeted therapeutics for MTAP-deleted cancers

      Download
    • pdf file

      Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors

      Download
    • pdf file

      Exploring Synthetic Lethality and Novel Drug Combinations in Patient-Derived Cells

      Download
    • pdf file

      Preclinical candidate RVU305, an MTA-cooperative, brain-permeable PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatment

      Download
    • pdf file

      Discovery of novel synthetic lethal targets for effective and safe colorectal cancer therapies

      Download

Stock info

Key Stock Details

Number of shares                               23 120 148

Number of votes                                  27 170 148

Nominal value of share                      0,40 zł

Bloomberg stock code                       RVU: PW

GPW Ticker                                             RVU

GPW Index                                               sWIG80

Media Pack

Download company assets

  • zip file

    Company logo pack

    Download
  • zip file

    Management board

    Download
  • zip file

    Labs

    Download
  • zip file

    Ryvu building

    Download
  • zip file

    About Ryvu

    Download

Contact
for Investors & Media

At Ryvu Therapeutics, we are dedicated to maintaining transparent and open communication with our media partners and investors. If you have any questions or require further information, please don’t hesitate to contact us at [email protected].